FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:KCNN1-GATA6

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: KCNN1-GATA6
FusionPDB ID: 41519
FusionGDB2.0 ID: 41519
HgeneTgene
Gene symbol

KCNN1

GATA6

Gene ID

3780

2627

Gene namepotassium calcium-activated channel subfamily N member 1GATA binding protein 6
SynonymsKCa2.1|SK1|SKCA1|hSK1-
Cytomap

19p13.11

18q11.2

Type of geneprotein-codingprotein-coding
Descriptionsmall conductance calcium-activated potassium channel protein 1potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 1potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1smalltranscription factor GATA-6GATA-binding factor 6
Modification date2020031320200313
UniProtAcc

Q92952

Main function of 5'-partner protein: FUNCTION: Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin (By similarity). {ECO:0000250}.

Q92908

Main function of 5'-partner protein: FUNCTION: Transcriptional activator (PubMed:19666519, PubMed:27756709, PubMed:22750565, PubMed:22824924). Regulates SEMA3C and PLXNA2 (PubMed:19666519). Involved in gene regulation specifically in the gastric epithelium (PubMed:9315713). May regulate genes that protect epithelial cells from bacterial infection (PubMed:16968778). Involved in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (By similarity). Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). In human skin, controls several physiological processes contributing to homeostasis of the upper pilosebaceous unit. Triggers ductal and sebaceous differentiation as well as limits cell proliferation and lipid production to prevent hyperseborrhoea. Mediates the effects of retinoic acid on sebocyte proliferation, differentiation and lipid production. Also contributes to immune regulation of sebocytes and antimicrobial responses by modulating the expression of anti-inflammatory genes such as IL10 and pro-inflammatory genes such as IL6, TLR2, TLR4, and IFNG. Activates TGFB1 signaling which controls the interfollicular epidermis fate (PubMed:33082341). {ECO:0000250|UniProtKB:Q61169, ECO:0000269|PubMed:16968778, ECO:0000269|PubMed:19666519, ECO:0000269|PubMed:22750565, ECO:0000269|PubMed:22824924, ECO:0000269|PubMed:27756709, ECO:0000269|PubMed:33082341, ECO:0000269|PubMed:9315713}.
Ensembl transtripts involved in fusion geneENST idsENST00000222249, ENST00000594192, 
ENST00000269216, ENST00000581694, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score5 X 6 X 3=907 X 5 X 5=175
# samples 57
** MAII scorelog2(5/90*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/175*10)=-1.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: KCNN1 [Title/Abstract] AND GATA6 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: KCNN1 [Title/Abstract] AND GATA6 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)KCNN1(18085996)-GATA6(19780619), # samples:3
Anticipated loss of major functional domain due to fusion event.KCNN1-GATA6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KCNN1-GATA6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
KCNN1-GATA6 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
KCNN1-GATA6 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
KCNN1-GATA6 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneGATA6

GO:0000122

negative regulation of transcription by RNA polymerase II

18177748

TgeneGATA6

GO:0006366

transcription by RNA polymerase II

19666519

TgeneGATA6

GO:0045766

positive regulation of angiogenesis

21127043

TgeneGATA6

GO:0045892

negative regulation of transcription, DNA-templated

18177748

TgeneGATA6

GO:0060575

intestinal epithelial cell differentiation

9566909

TgeneGATA6

GO:0070848

response to growth factor

21127043

TgeneGATA6

GO:0071158

positive regulation of cell cycle arrest

9593712

TgeneGATA6

GO:0071456

cellular response to hypoxia

21127043

TgeneGATA6

GO:0110024

positive regulation of cardiac muscle myoblast proliferation

25068583



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:18085996/chr18:19780619)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across KCNN1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across GATA6 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000222249KCNN1chr1918085996+ENST00000581694GATA6chr1819780619+1042817226984252

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000222249ENST00000581694KCNN1chr1918085996+GATA6chr1819780619+0.0086929230.9913071

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for KCNN1-GATA6

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
KCNN1chr1918085996GATA6chr1819780619817196LLGLVVLYHAREIQAGAPVMTGAGES

Top

Potential FusionNeoAntigen Information of KCNN1-GATA6 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KCNN1-GATA6_18085996_19780619.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:06YHAREIQA0.99950.8749715
KCNN1-GATA6chr1918085996chr1819780619817HLA-B15:03IQAGAPVM0.98140.89811220
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:01REIQAGAP0.96260.87781018
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:02REIQAGAPV0.99960.54271019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:02REIQAGAPV0.99610.78241019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:01REIQAGAPV0.99460.78161019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B45:01REIQAGAPV0.99140.95451019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B56:01HAREIQAGA0.85740.7093817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:13REIQAGAPV0.83040.98971019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:05REIQAGAPV0.73710.65891019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:01REIQAGAPV0.67950.91281019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B41:01REIQAGAPV0.66740.96711019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:01REIQAGAPVM0.99540.80711020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:06YHAREIQAGA0.99340.9793717
KCNN1-GATA6chr1918085996chr1819780619817HLA-B47:01REIQAGAPVM0.98990.70741020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:13REIQAGAPVM0.9560.99221020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:05REIQAGAPVM0.94680.65171020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:05YHAREIQA0.99780.8054715
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:06REIQAGAPV0.99960.94881019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B48:03REIQAGAPV0.99520.81591019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B54:01HAREIQAGA0.9740.8991817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:03REIQAGAPV0.93350.60591019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:08REIQAGAPV0.77270.92421019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B78:01HAREIQAGA0.35530.9014817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:06REIQAGAPVM0.99860.92661020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B48:03REIQAGAPVM0.9950.83291020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:03REIQAGAPVM0.98460.67951020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:08REIQAGAPVM0.96270.96481020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B15:73IQAGAPVM0.99230.99351220
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:04REIQAGAP0.96260.87781018
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:05REIQAGAP0.96260.87781018
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:40REIQAGAPV0.99950.58241019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:04REIQAGAPV0.99820.93791019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:12REIQAGAPV0.99520.81591019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:36REIQAGAPV0.99490.76321019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:49REIQAGAPV0.99350.7931019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B55:02HAREIQAGA0.82580.6974817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B41:03REIQAGAPV0.81360.77871019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B56:05HAREIQAGA0.79090.772817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:02REIQAGAPV0.75970.98951019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:04REIQAGAPV0.67950.91281019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B50:05REIQAGAPV0.67950.91281019
KCNN1-GATA6chr1918085996chr1819780619817HLA-B78:02HAREIQAGA0.28350.9449817
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:40REIQAGAPVM0.99940.52551020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:04REIQAGAPVM0.9960.96491020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:12REIQAGAPVM0.9950.83291020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:49REIQAGAPVM0.99490.81561020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B40:36REIQAGAPVM0.99480.77841020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B15:53REIQAGAPVM0.98220.95671020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B39:02REIQAGAPVM0.95490.99121020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B48:02REIQAGAPVM0.84880.96161020
KCNN1-GATA6chr1918085996chr1819780619817HLA-B41:03REIQAGAPVM0.72990.84761020

Top

Potential FusionNeoAntigen Information of KCNN1-GATA6 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KCNN1-GATA6_18085996_19780619.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1102GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1103GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1116GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1121GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1148GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1155GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1163GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1165GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1170GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1176GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1185GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1301GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1308GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1317GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1322GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1324GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1335GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1351GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1352GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1359GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1361GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1364GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1368GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1369GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1370GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1372GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1376GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1379GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1380GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1383GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1384GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1387GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1391GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1392GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1398GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1501LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1501LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1501GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1502LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1502LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1503LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1503GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1503LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1504LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1504GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1504LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1505LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1505LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1505GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1506LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1506LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1506GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1507LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1507LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1507GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1508LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1508LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1509LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1509LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1509GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1510LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1510GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1510LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1511LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1512LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1512LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1512GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1513LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1513LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1513GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1514LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1514LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1515LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1516LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1516LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1516GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1518LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1518GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1518LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1519LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1519LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1520LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1520LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1520GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1521LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1521LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1521GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1522LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1522LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1522GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1523LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1523GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1524LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1524LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1524GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1526LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1526LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1528LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1528LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1528GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1529LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1529LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1530LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1530LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1531LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1531LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1532LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1532LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1532GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1533LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1533LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1533GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1535LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1535LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1535GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1536LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1536LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1536GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1537LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1537LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1537GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1538LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1538LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1539LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1539LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1540LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1540LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1540GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1541LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1541LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1541GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1542LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1542LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1542GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1543LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1543LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1543GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1544LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1544LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1545LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1545LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1545GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1546LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1546LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1546GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1547LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1547LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1548LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1548LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1548GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1549LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1549LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB1-1549GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB5-0202LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB5-0202LLGLVVLYHAREIQA015
KCNN1-GATA6chr1918085996chr1819780619817DRB5-0202GLVVLYHAREIQAGA217
KCNN1-GATA6chr1918085996chr1819780619817DRB5-0204LGLVVLYHAREIQAG116
KCNN1-GATA6chr1918085996chr1819780619817DRB5-0204GLVVLYHAREIQAGA217

Top

Fusion breakpoint peptide structures of KCNN1-GATA6

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5831LYHAREIQAGAPVMKCNN1GATA6chr1918085996chr1819780619817

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of KCNN1-GATA6

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5831LYHAREIQAGAPVM-6.90681-7.02021
HLA-B14:023BVN5831LYHAREIQAGAPVM-4.76457-5.79987
HLA-B52:013W395831LYHAREIQAGAPVM-6.73002-7.76532
HLA-B52:013W395831LYHAREIQAGAPVM-5.97102-6.08442
HLA-A24:025HGA5831LYHAREIQAGAPVM-7.16156-7.27496
HLA-A24:025HGA5831LYHAREIQAGAPVM-4.77733-5.81263
HLA-B44:053DX85831LYHAREIQAGAPVM-6.41424-6.52764
HLA-B44:053DX85831LYHAREIQAGAPVM-3.42783-4.46313

Top

Vaccine Design for the FusionNeoAntigens of KCNN1-GATA6

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
KCNN1-GATA6chr1918085996chr18197806191018REIQAGAPGAGATCCAGGCGGGTGCCCCGGTG
KCNN1-GATA6chr1918085996chr18197806191019REIQAGAPVGAGATCCAGGCGGGTGCCCCGGTGATG
KCNN1-GATA6chr1918085996chr18197806191020REIQAGAPVMGAGATCCAGGCGGGTGCCCCGGTGATGACT
KCNN1-GATA6chr1918085996chr18197806191220IQAGAPVMCAGGCGGGTGCCCCGGTGATGACT
KCNN1-GATA6chr1918085996chr1819780619715YHAREIQACATGCCCGGGAGATCCAGGCGGGT
KCNN1-GATA6chr1918085996chr1819780619717YHAREIQAGACATGCCCGGGAGATCCAGGCGGGTGCCCCG
KCNN1-GATA6chr1918085996chr1819780619817HAREIQAGAGCCCGGGAGATCCAGGCGGGTGCCCCG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
KCNN1-GATA6chr1918085996chr1819780619015LLGLVVLYHAREIQACTGGGTCTCGTTGTCCTCTACCATGCCCGGGAGATCCAGGCGGGT
KCNN1-GATA6chr1918085996chr1819780619116LGLVVLYHAREIQAGGGTCTCGTTGTCCTCTACCATGCCCGGGAGATCCAGGCGGGTGCC
KCNN1-GATA6chr1918085996chr1819780619217GLVVLYHAREIQAGACTCGTTGTCCTCTACCATGCCCGGGAGATCCAGGCGGGTGCCCCG

Top

Information of the samples that have these potential fusion neoantigens of KCNN1-GATA6

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
UCECKCNN1-GATA6chr1918085996ENST00000222249chr1819780619ENST00000581694TCGA-AJ-A2QM-01A

Top

Potential target of CAR-T therapy development for KCNN1-GATA6

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneKCNN1chr19:18085996chr18:19780619ENST00000222249+411111_131166544.0TransmembraneHelical%3B Name%3DSegment S1
HgeneKCNN1chr19:18085996chr18:19780619ENST00000222249+411140_160166544.0TransmembraneHelical%3B Name%3DSegment S2

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to KCNN1-GATA6

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to KCNN1-GATA6

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource